126 results about "Mast cell" patented technology

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

The invention discloses a novel application of bifidobacterium longum subsp. Infantis CCFM1269 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. Infantis CCFM1269 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mast cell infiltration is reduced; (2) reducing the total IgE level of serum; (3) the Treg level of mesenteric lymph nodes and the ILA content of serum are improved; (4) IL-4 and TSLP levels in skin tissues are reduced, IL-10 is improved, and Th1 / Th2 immune balance is recovered; (5) improving AHR and CYP1A1 in the skin tissue; and (4) high yield of ILA.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

The invention belongs to the technical field of biological medicines, and particularly relates to application of quercetin combined with curcumin in preparation of an anti-allergic reaction medicine. Through a large number of researches, the inventor finds that combined administration of quercetin and curcumin with a specific concentration can effectively inhibit mast cell degranulation, and the inhibition rate of mast cell degranulation reaches 90% or more, so that I-type anaphylaxis mediated by immune globulin E is inhibited, especially systemic anaphylaxis, and the curative effect is good. The compound can be used for preparing anti-anaphylaxis drugs. The drug combination scheme provided by the invention has important significance and wide application prospect in drugs for treating or preventing anaphylactic reactions.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention provides a specific binding polypeptide of a targeted cell membrane receptor Fc epsilon RI alpha and application of the specific binding polypeptide. The amino acid sequence of the polypeptide is shown in any one of (I) SEQ ID NO: 1-6; (II) an amino acid sequence with at least 90% identity as shown in any one of SEQ ID NO: 1-6, and is specifically combined with a cell membrane receptor Fc epsilon RI alpha. Experimental results show that the Fc [epsilon] RI [alpha] specific binding polypeptide can inhibit IgE-mediated mast cell dependent anaphylaxis to a certain extent, which prompts that the Fc [epsilon] RI [alpha] specific binding polypeptide has a certain inhibition effect on IgE-mediated I-type anaphylaxis, and lays a foundation for further research and development of novel biological targeting drugs for treating allergic diseases.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-glisoquinolin-5-yl]-3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

The invention provides methods and compositions that are useful for treating allergic diseases, bacterial infections, fungal infections, viral infections, mastocytosis, mast cell-mediated inflammation and parasite infections (e.g., helminth infections).

The present invention relates to a composition for improving skin, which comprises beta-sitosterol and betulin and, in the case of the composition, reduces dermatoneuropathic stimulation-inducing factors, increases the expression of moisturizing-related factors, increases skin absorbance, improves skin penetration, inhibits mast cell activity, and improves skin quality. Thus, it has been confirmed that the composition has excellent skin-calming and skin-irritation-relieving effects, and thus can be usefully used in skin-improving cosmetics, pharmaceuticals, and the like.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

Disclosed are compounds having the formula (I), or an enantiomer, diastereomer, or tautomer or atropisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, A and n are defined herein. Also disclosed are methods of preparing such compounds, as well as pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of inflammatory disorders, allergic disorders, skin disorders, mast cell disorders, pain disorders, and pruritus disorders. (I)

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The application provides an anti-urticaria traditional Chinese medicine composition, a medicine preparation and a preparation method and application, and belongs to the field of traditional Chinese medicine compositions. The traditional Chinese medicine composition is composed of the following raw materials: 12-18 parts of Fructus Mume, 8-12 parts of Glycyrrhiza, 12-18 parts of Imperata Cylindra, 8-12 parts of Smilax Glabra, 8-12 parts of Coix Lachryma-jobi, 8-12 parts of Radix Angelicae Dahuricae, 5-7 parts of Mentha, 5-7 parts of Astragalus, 8-12 parts of Pericarpium Citri Reticulatae, and 8-12 parts of Momordica Grosvenorii. The composition follows the compatibility principle of monarch, minister, assistant and messenger, has mild medicinal properties, can significantly improve the histopathological damage of skin tissues, reduce the infiltration of mast cells, reduce the serum IgE level, correct the Th1 / Th2 immune deviation by up-regulating the Th1-type cytokine IFN-gamma and down-regulating the Th2-type cytokines IL-4, IL-5 and IL-13, and reconstruct the local immune homeostasis of skin, and has significant advantages in relieving the symptoms of urticaria and reducing the recurrence.

The invention relates to a method for depleting mast cells. The invention also relates to a method of treating mast cell disease in a subject in need thereof. The method involves administering an anti-mast cell antibody wherein the antibody is administered by a slow absorption delivery pathway, in particular wherein the antibody is administered subcutaneously. Administration of anti-mast cell antibodies via a slow absorption delivery pathway (e.g., subcutaneous or intradermal) can avoid allergic reactions occurring when anti-mast cell antibodies are administered via other pathways (e.g., intravenous).

This disclosure relates to methods of treating cancer comprising administering an effective amount of a platinum-based chemotherapy agent in combination with a microtubule associated serine / threonine-protein kinase (MAST) inhibitor and / or a glucocorticoid receptor binding agent and / or a hsp90 binding agent and / or other chemotherapy agents disclosed herein to a subject in need thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising combinations of agents disclosed herein and a pharmaceutically acceptable excipient.

The present disclosure relates to the use of IgE for identifying individuals with genetic defects that lead to the expression of protein truncations, extended proteins, to a loss of protein expression or to the expression of mutated proteins. The method is based on a skin prick test, wherein IgE that is specific for the protein of interest is administered onto the skin. If the protein or protein variant that is specifically identified by IgE is present in the skin, the IgE, which was allowed to enter the skin by the skin prick, binds the target protein and then the protein-bound IgE triggers mast cells and / or basophiles in the skin to release granules, resulting in the development of a transient allergic reaction.

The invention discloses a near-infrared ratio type fluorescent probe for rapidly and reversibly detecting histamine (HA), a preparation method of the fluorescent probe and application of the fluorescent probe in dynamic cell imaging, and belongs to the technical field of fluorescence imaging and biosensing. The preparation method comprises the following specific steps: synthesizing aza-BODIPY molecules (1a-1d, 2a-2d) with different halogenations, and meanwhile, connecting the aza-BODIPY molecules with hydroxyl groups at 3 and 5 sites with a hydrophilic PEG (Polyethylene Glycol) fragment and halogen to obtain an HA probe HAPCyto with good water solubility; in addition, the hydroxyl aza-BODIPY molecules are continuously subjected to substitution, halogenation and hydrolysis reaction to obtain carboxyl-containing aza-BODIPY molecules, then the aza-BODIPY molecules are subjected to amidation reaction by utilizing the site, and different organic fragments are respectively connected to obtain a cell membrane targeted HA probe HAPPM, a golgi apparatus targeted HA probe HAPGA and a HaloTag HA fluorescent probe HAPHaloTag. When HA exists in a solution, the developed probe can realize rapid reversible detection of the near-infrared ratio of histamine, also shows good reversible property in mast cells, and can realize dynamic monitoring of histamine in cells.

The invention relates to the field of medicines, in particular to application of LKB1 / AMPK pathway-based fucoidan in preparation of anti-type I anaphylaxis medicines. The LKB1 / AMPK pathway is activated by the alginate, so that mast cell degranulation is effectively inhibited, mast cell mediated cell anaphylaxis is further effectively inhibited, and the alginate can be used for preparing anti-anaphylaxis related drugs.

The present invention relates to a composition for preventing, alleviating or treating skin wounds, comprising exosomes of mast cells. The composition according to the present invention enhances the growth and activity of fibroblasts, and thus has the effects of significantly reducing the size of wounds and shortening an initial wound treatment period.

The invention discloses an application of a nitrobenzene-containing urea compound in preparation of an anti-allergic reaction drug, and the nitrobenzene-containing urea compound can be applied in preparation of a drug for antagonizing mouse sole swelling and plasma exosmosis caused by C48 / 80. The invention also discloses application of the compound in preparation of drugs for antagonizing mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80. The nitrobenzene-containing urea compound can effectively relieve mouse sole swelling and plasma exosmosis, mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80, reduce serum histamine release and relieve body temperature decline, so that the occurrence of anaphylactoid reaction is inhibited, and the nitrobenzene-containing urea compound can be used for preventing and treating hyperplasia. Therefore, when the nitrobenzene-containing urea compound is used as an anti-drug anaphylaxis preparation, more possible treatment schemes are provided for clinical drug anaphylaxis treatment.

The invention provides pediococcus acidilactici with functions of improving emotion and intestinal health and application of the pediococcus acidilactici. The pediococcus acidilactici A25-4 is preserved in Guangdong Microbial Culture Collection Center on May 23, 2025, and the preservation number of the pediococcus acidilactici A25-4 is GDMCC NO: 66384. The pediococcus acidilactici A25-4 has better cholate resistance and artificial gastrointestinal fluid resistance and can produce indole lactic acid ILA at high yield, and the optimal carbon source is fructo-oligosaccharide and galactooligosaccharide. The pediococcus acidilactici A25-4 in-vivo intervention can significantly improve the symptoms of an irritable bowel syndrome model mouse, specifically, the anxiety mood of a tested object is significantly improved; the viscera hypersensitivity of a tested object is obviously relieved; excessive activation of mast cells of a tested object is obviously inhibited; the ILA level in a tested object is obviously improved.

The present application relates to the technical field of skin care products, and discloses a composition with the effect of soothing sensitive skin, which is composed of the following components in mass percentage: plant extract 10-12%, skin repair factor 2-3%, jasmine hydrolat 10%, humectant 6-7%, and the balance being water. The composition with the effect of soothing sensitive skin has significant soothing effect, which is close to the soothing effect of common hormone ointments on the market. The composition can significantly reduce inflammatory factors, has good anti-inflammatory effect, simultaneously repairs damaged skin, enhances the moisturizing function, and enhances the skin barrier through the moisturizing and repairing effect. The composition has the effect of resisting anaphylaxis by reducing the content of trypsin and inhibiting the allergic reaction of mast cells. Human patch test and fish embryo development toxicity test prove that the composition with the effect of soothing sensitive skin has no skin adverse reactions and no development toxicity, is mild, safe and non-irritating, and is suitable for preparing skin care products for adults and infants.

The invention discloses application of transgenic zebrafish in preparation of an animal model capable of visually monitoring mast cells. The transgenic zebrafish is prepared by the following method: respectively carrying out XhoI and BamHI double enzyme digestion on a cpa5 gene promoter sequence (SEQ ID NO: 1) and plasmids with fluorescent protein genes and Tol2 transposon recognition sites, and then connecting to obtain recombinant plasmids; and then introducing the recombinant plasmid and Tol2 transposase mRNA into a zebra fish embryo in a microinjection mode in a 1-cell period of zebra fish embryo development, and culturing at constant temperature to obtain the transgenic zebra fish. The cpa5 promoter is constructed to drive an expression framework of the fluorescent protein, so that the mast cells naturally emit fluorescence in the zebra fish body, and an effective animal model is provided for mechanism research and drug screening of mast cell related diseases.

The invention relates to the field of allergic rhinitis, and discloses an application of sodium hyaluronate in preparation of an external medicine for treating allergic rhinitis. Based on actual clinical efficacy verification, the mechanism of sodium hyaluronate playing efficacy is that sodium hyaluronate can be used for preparing an external medicine for treating allergic rhinitis; sodium hyaluronate is used for reducing drainage lymph nodes in an atopic individual area and generating specificity I gE by nasal submucosa plasma cells, blocking contact between allergens and the surface specificity I gE of sensitized mast cells or sensitized basophilic granulocytes in a sensitized body, stopping development of anaphylaxis and promoting subduing of nasal mucosa inflammation, so that allergy symptoms are eliminated, and the nasal mucosa inflammation eliminating effect is achieved. According to the embodiment of the invention, the result of treating AR by adopting HA nasal drops shows that an obvious effect is achieved 1-2 days after the medicine is taken, the medicine takes effect quickly, the safety is relatively high, and the medicine can be used as a new product for industrial reproducible production.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

The invention belongs to the technical field of food microorganisms, and particularly relates to a lactobacillus paracasei BHP06 with an anti-allergic function. The preservation number of the Lactobacillus paracasei BHP06 is GDMCC (China General Microbiological Culture Collection Center) No: 66270, and the preservation number of the Lactobacillus paracasei BHP06 is CGMCC No: 66270. The lactobacillus paracasei strain provided by the invention has good gastrointestinal tract reverse environment resistance and has good survival ability in simulated gastrointestinal fluid; good self-aggregation capability and hyaluronidase inhibition capability are realized. By establishing a degranulation model of RBL-2H3 cells, it is found that the strain can inhibit mast cell degranulation and relieve allergy; by establishing an RAW264.7 cell inflammation model, the strain disclosed by the invention is found to be capable of inhibiting allergic inflammatory reaction; by establishing an OVA (ovalbumin)-induced BALB / c mouse food allergy model, the strain disclosed by the invention is found to be capable of improving the anti-allergy ability of animals and exerting the activity of relieving food allergy.